Ionis Pharmaceuticals' olezarsen treatment shows positive Phase 3 results for familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.

Ionis Pharmaceuticals announced positive Phase 3 results for its olezarsen treatment for familial chylomicronemia syndrome (FCS). Olezarsen significantly reduced triglycerides and serum apolipoprotein C-III levels in genetically validated FCS patients, and reduced acute pancreatitis events compared to placebo. Ionis plans to pursue regulatory approval for olezarsen as a potential breakthrough treatment for adults with FCS.